Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Non-randomized, Open-label, Phase 2 Study
scientific article published on 08 November 2018
Author/s
author: Jorge Eduardo Cortes, Jing Ning, Michael Andreeff, James P. Allison, Naveen Pemmaraju, Guillermo Garcia-Manero, Keyur P Patel, Steven M Kornblau, Elias Jabbour, Marina Konopleva, Courtney D DiNardo, Tapan M Kadia, Carlos B Bueso-Ramos, Graciela M Nogueras-Gonzalez, Jeffrey C. Jorgensen, Hagop Kantarjian, Farhad Ravandi-Kashani, Naval Daver, Mansour Alfayez, Sreyashi Basu, Jorge M Blando, Padmanee Sharma
Work details
Copyright status
Copyright status information is not available for this work. The copyright status depends on the jurisdiction, the author's date of death and the date the work was created or published.
To learn more about copyright terms in different countries, visit the countries and terms page.